UGT1A1 and cancer: Due to the differences in genetic background, the differences in UGT1A1 mutation sites and mutation frequencies are important reasons for the obvious differences in the efficacy and incidence of adverse reactions between different cancer populations in Eastern and Western countries when receiving IRI treatment.